Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.65 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517648 | 0.84 | FFAR1 (0.71) | FFAR1FFAR4MAOBS1PR1S1PR5 | |
| SCHEMBL13140348 | 0.83 | FFAR1 (0.70) | FFAR1FFAR4MAOBS1PR1S1PR5 | |
| SCHEMBL13118275 | 0.82 | FFAR1 (0.58) | FFAR1FFAR4MAOB | |
| SCHEMBL13140194 | 0.81 | FFAR1 (0.67) | FFAR1FFAR4MAOBS1PR1S1PR5 | |
| SCHEMBL1508359 | 0.79 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL1508525 | 0.79 | FFAR1 (0.74) | FFAR1FFAR4MAOBS1PR1S1PR5 | |
| SCHEMBL13140230 | 0.78 | FFAR1 (0.63) | FFAR1FFAR4MAOBS1PR1S1PR5 | |
| SCHEMBL3519075 | 0.78 | FFAR1 (0.76) | FFAR1 | |
| SCHEMBL3518778 | 0.78 | FFAR1 (0.76) | FFAR1 | |
| SCHEMBL3523242 | 0.78 | FFAR1 (0.76) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | FFAR1 1245/4885FFAR4 1372/4885MAOB 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.